{"id":"switch-to-tdf-ftc-rpv-after-24-weeks","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Renal impairment (TDF-related)"},{"rate":null,"effect":"Bone density loss (TDF-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TDF (tenofovir disoproxil fumarate) and FTC (emtricitabine) are nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase, while RPV (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor that binds directly to the enzyme. Together, these three agents provide potent suppression of HIV viral replication through dual inhibition of reverse transcriptase.","oneSentence":"A combination antiretroviral regimen that suppresses HIV replication by inhibiting reverse transcriptase and integrase through three complementary agents.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:26.627Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced or treatment-naive patients"}]},"trialDetails":[{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02042001","phase":"PHASE4","title":"Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects","status":"COMPLETED","sponsor":"Azienda Ospedaliera San Gerardo di Monza","startDate":"2015-07-01","conditions":"Impaired Cognition, Depression/Anxiety, Poor Quality Sleep","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eviplera(r)"],"phase":"marketed","status":"active","brandName":"Switch to TDF/FTC/RPV after 24 weeks","genericName":"Switch to TDF/FTC/RPV after 24 weeks","companyName":"Azienda Ospedaliera San Gerardo di Monza","companyId":"azienda-ospedaliera-san-gerardo-di-monza","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination antiretroviral regimen that suppresses HIV replication by inhibiting reverse transcriptase and integrase through three complementary agents. Used for HIV-1 infection in treatment-experienced or treatment-naive patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}